EGFR and non-small cell lung carcinoma: Furthermore, combining CHIR-99021 with gefitinib [206] significantly enhances the sensitivity of NSCLC cells to gefitinib in MTSCs, regardless of epidermal growth factor receptor (EGFR) mutation.